选择成功的降脂治疗

《选择成功的降脂治疗》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。

1、SelectingSuccessfulLipid-LoweringTreatmentsJamesM.McKenney,Pharm.D.ExpertPanelonDetection,Evaluation,andTreatmentofHighBloodCholesterolinAdults.JAMA2001;285:2486-2497.TreatmentCategories,LDL-CGoalsandCutpointsRiskCategoryLDL-CGoalConsiderDrugTherapyCHDorCHDriskequiva

2、lent<100mg/dL130mg/dL*2RiskFactors10-yrrisk10–20%10-yrrisk<10%<130mg/dL<130mg/dL130mg/dL160mg/dL<2RiskFactors<160mg/dL190mg/dL*100–129mg/dL=afterTLC,considerstatin,niacin,orfibratetherapyTreatmentofHyperlipidemiaExpertPanelonDetection,Evaluation,andTreatmentofHigh

3、BloodCholesterolinAdults.JAMA2001;285:2486-2497.HighLDL-CTherapeuticLifestyleChangeDrugTherapyTherapyofChoice:StatinAlternative:ResinorniacinStatins:MechanismofActionLDLreceptor–mediatedhepaticuptakeofLDLandVLDLremnantsSerumVLDLremnantsSerumLDL-CCholesterolsynthesisLDL

4、receptor(B–Ereceptor)synthesisIntracellularCholesterolApoBApoEApoBSystemicCirculationHepatocyteReducehepaticcholesterolsynthesis,loweringintracellularcholesterol,whichstimulatesupregulationofLDLreceptorandincreasestheuptakeofnon-HDLparticlesfromthesystemiccirculation.L

5、DLSerumIDLVLDLRVLDLTheLDL-C–LoweringEfficacyoftheCurrentlyAvailableStatinsPhysician’sDeskReference.55thed.Montvale,NJ:MedicalEconomics,2001.DailyDoseAtorvaFluvaLovaPravaSimva10mg–39%–22%–30%20mg–43%–22%–27%–32%–38%40mg–50%–25%–32%–34%–41%80mg–60%–36%–42%–47%TheTriglyce

6、ride-LoweringEffectsofStatinsSteinEAetal.AmJCardiol1998;81:66B-69B.BaselineTG(mg/dL)<150150–250>250Lova20mg1%–9%–32%Prava10mg6%–11%–22%Simva10mg1%–20%–28%*NonfatalMIorCHDdeath;**ischemiceventsDownsJRetal.JAMA1998;279:1615-1622.

7、ShepherdJetal.NEnglJMed1999;333:1301-130

8、7.

9、ScandinavianSimvastatinStudyGroup.Lancet1994;344:1383-1389.

10、SacksFMetal.NEnglJMed1996;335:1001-1009.

11、LIPIDStudyGroup.NEnglJMed1998;339:1349-1357.

12、SchwartzGGetal.JAMA2001;285:1711-1718.

13、PittBetal.NEnglJMed1999;341:70-76.EndpointTrialswiththeStatinsTrialDrugCHDRiskRed

14、uctionPrimaryPreventionAFCAPS/TexCAPSLovastatin–40%*WOSCOPSPravastatin–31%*SecondaryPrevention4SSimvastatin–34%*CAREP